See more : FCR Immobilien AG (FCRIF) Income Statement Analysis – Financial Results
Complete financial analysis of Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shandong Sinobioway Biomedicine Co., Ltd., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Irwin Resources, Inc. (IWRS) Income Statement Analysis – Financial Results
- RoodMicrotec N.V. (ROOD.AS) Income Statement Analysis – Financial Results
- LAN & SPAR INVEST (LSIB60.CO) Income Statement Analysis – Financial Results
- EKF Diagnostics Holdings plc (EKF.L) Income Statement Analysis – Financial Results
- Catvision Limited (CATVISION.BO) Income Statement Analysis – Financial Results
Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ)
About Shandong Sinobioway Biomedicine Co., Ltd.
Shandong Sinobioway Biomedicine Co., Ltd. manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, nerve growth factor, and alfaron in China. The company also provides NOBEX, a murine nerve growth factor for injection; Anferon, a human recombinant interferon alpha 2b injection; and Jaferon, a human recombinant interferon alpha 2b spray. In addition, it offers Healive, an inactivated hepatitis A vaccine; Bilive, a combined hepatitis A and B Vaccine; Panflu, a pandemic influenza vaccine; Anflu, a preservative-free influenza virus vaccine; Panflu.1, a Type A H1N1 influenza vaccine; etc. Further, the company exports its products to approximately 20 counties and regions in Europe and the United States. Shandong Sinobioway Biomedicine Co., Ltd. was founded in 2000 and is headquartered in Zibo, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 429.79M | 357.08M | 402.71M | 276.83M | 567.64M | 664.59M | 1.16B | 1.26B | 858.29M | 319.14M | 317.25M | 285.34M | 246.37M | 247.17M | 213.80M | 177.25M | 150.03M |
| Cost of Revenue | 93.29M | 76.21M | 85.83M | 54.33M | 74.14M | 98.55M | 255.66M | 299.35M | 142.41M | 191.62M | 178.09M | 157.95M | 128.66M | 128.86M | 110.18M | 111.03M | 90.65M |
| Gross Profit | 336.50M | 280.87M | 316.88M | 222.50M | 493.50M | 566.04M | 906.75M | 965.53M | 715.88M | 127.52M | 139.16M | 127.40M | 117.71M | 118.31M | 103.62M | 66.22M | 59.38M |
| Gross Profit Ratio | 78.29% | 78.66% | 78.69% | 80.38% | 86.94% | 85.17% | 78.01% | 76.33% | 83.41% | 39.96% | 43.86% | 44.65% | 47.78% | 47.87% | 48.47% | 37.36% | 39.58% |
| Research & Development | 59.80M | 27.29M | 38.44M | 49.30M | 54.66M | 45.95M | 39.02M | 44.00M | 29.44M | 12.20M | 12.01M | 11.49M | 10.76M | 11.24M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 117.18M | 82.82M | 89.33M | 93.37M | 73.08M | 89.27M | 59.21M | 52.86M | 37.35M | 6.05M | 6.95M | 9.18M | 12.55M | 5.44M | 22.13M | 15.14M | 13.65M |
| Selling & Marketing | 288.30M | 292.48M | 345.33M | 286.24M | 422.46M | 394.60M | 389.24M | 408.65M | 347.40M | 12.90M | 13.19M | 10.64M | 7.92M | 8.89M | 8.42M | 7.30M | 8.31M |
| SG&A | 405.48M | 375.30M | 434.66M | 379.61M | 495.53M | 483.87M | 448.46M | 461.51M | 384.75M | 18.95M | 20.14M | 19.82M | 20.48M | 14.33M | 30.55M | 22.45M | 21.97M |
| Other Expenses | 144.32M | 45.69M | 35.02M | 31.46M | 31.87M | 14.49M | -1.01M | 9.54M | 5.95M | 1.40M | 884.63K | 328.04K | 883.54K | 309.72K | -1.85M | -348.13K | -1.01M |
| Operating Expenses | 629.85M | 448.27M | 508.12M | 460.37M | 582.06M | 560.31M | 503.25M | 537.87M | 436.69M | 43.92M | 43.85M | 41.09M | 41.69M | 33.83M | 30.55M | 22.45M | 21.97M |
| Cost & Expenses | 723.14M | 524.49M | 593.96M | 514.70M | 656.20M | 658.86M | 758.91M | 837.22M | 579.10M | 235.54M | 221.95M | 199.04M | 170.35M | 162.69M | 140.73M | 133.48M | 112.61M |
| Interest Income | 1.72M | 3.02M | 3.75M | 17.20M | 73.29M | 32.56M | 20.94M | 11.07M | 8.25M | 10.22M | 9.13M | 15.22M | 3.65M | 223.83K | -0.98 | -0.35 | 411.70K |
| Interest Expense | 8.64M | 9.41M | 6.88M | 25.43M | 40.86M | 78.16M | 15.01M | 5.00M | 16.60M | 13.40M | 8.63M | 51.09K | 405.78K | 949.77K | 935.97K | 867.31K | 12.50K |
| Depreciation & Amortization | 70.63M | 77.45M | 69.45M | 63.68M | 61.00M | 62.13M | 53.83M | 56.54M | 42.41M | 12.65M | 7.31M | 7.43M | 7.92M | 7.47M | 8.03M | 6.53M | 3.89M |
| EBITDA | -233.98M | 106.07M | 351.25M | -116.68M | 163.86M | 30.24M | 527.97M | 496.06M | 328.96M | 228.39M | 104.23M | 108.83M | 87.44M | 92.63M | 81.10M | 49.99M | 41.35M |
| EBITDA Ratio | -54.44% | 29.70% | 87.76% | -22.06% | 28.87% | 35.70% | 47.11% | 41.57% | 40.66% | 30.12% | 32.85% | 38.15% | 35.70% | 37.41% | 38.29% | 28.50% | 27.09% |
| Operating Income | -293.35M | 33.67M | 273.08M | -237.87M | 105.86M | -87.24M | 465.17M | 449.18M | 276.09M | 94.29M | 102.33M | 101.09M | 78.24M | 83.90M | 71.39M | 42.70M | 39.10M |
| Operating Income Ratio | -68.25% | 9.43% | 67.81% | -85.92% | 18.65% | -13.13% | 40.02% | 35.51% | 32.17% | 29.54% | 32.26% | 35.43% | 31.76% | 33.94% | 33.39% | 24.09% | 26.06% |
| Total Other Income/Expenses | -19.90M | -20.95M | 5.52M | -6.10M | -2.24M | -1.77M | -1.04M | 9.35M | 5.87M | 43.68M | 884.63K | 308.07K | 883.54K | 309.72K | -1.86M | -1.21M | -1.63M |
| Income Before Tax | -313.25M | 12.72M | 278.60M | -201.76M | 76.77M | -89.01M | 464.13M | 456.56M | 281.96M | 95.69M | 103.22M | 101.39M | 79.12M | 84.21M | 69.52M | 42.35M | 37.46M |
| Income Before Tax Ratio | -72.88% | 3.56% | 69.18% | -72.88% | 13.52% | -13.39% | 39.93% | 36.10% | 32.85% | 29.98% | 32.53% | 35.53% | 32.12% | 34.07% | 32.52% | 23.89% | 24.97% |
| Income Tax Expense | 8.89M | 13.59M | -90.79K | -3.59M | 3.68M | 9.21M | 73.22M | 40.05M | 41.66M | 14.21M | 15.18M | 15.12M | 12.15M | 13.95M | 10.70M | 5.30M | 4.83M |
| Net Income | -332.46M | -868.19K | 271.00M | -198.18M | 63.38M | -95.79M | 388.41M | 417.70M | 250.25M | 81.48M | 88.04M | 86.27M | 66.98M | 70.26M | 58.82M | 37.04M | 32.63M |
| Net Income Ratio | -77.35% | -0.24% | 67.29% | -71.59% | 11.17% | -14.41% | 33.41% | 33.02% | 29.16% | 25.53% | 27.75% | 30.23% | 27.19% | 28.42% | 27.51% | 20.90% | 21.75% |
| EPS | -0.50 | 0.00 | 0.41 | -0.30 | 0.10 | -0.15 | 0.59 | 0.63 | 0.56 | 0.59 | 0.32 | 0.31 | 0.27 | 0.33 | 0.28 | 0.18 | 0.18 |
| EPS Diluted | -0.50 | 0.00 | 0.41 | -0.30 | 0.10 | -0.15 | 0.59 | 0.63 | 0.56 | 0.59 | 0.32 | 0.31 | 0.27 | 0.33 | 0.28 | 0.18 | 0.18 |
| Weighted Avg Shares Out | 659.77M | 659.74M | 659.74M | 659.74M | 659.74M | 659.58M | 659.74M | 659.74M | 446.88M | 381.37M | 279.48M | 282.86M | 252.37M | 209.96M | 212.42M | 200.65M | 180.52M |
| Weighted Avg Shares Out (Dil) | 659.77M | 659.74M | 659.74M | 659.74M | 659.74M | 659.58M | 659.78M | 659.76M | 448.56M | 381.37M | 279.48M | 282.86M | 252.37M | 209.96M | 212.42M | 200.65M | 180.52M |
Source: https://incomestatements.info
Category: Stock Reports